[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nThe vignette describes the classic clinical phenotype of anti-IgLON5 disease, a distinct autoimmune tauopathy. The key discriminating features are the specific sleep architecture (coexistence of REM sleep behavior disorder and non-REM parasomnias), nocturnal stridor (due to laryngeal dysfunction), gait instability, and cognitive decline. These findings point uniquely to Option C. The distractors are incorrect: Anti-Hu and Anti-Yo are typically associated with paraneoplastic sensory neuronopathy or cerebellar degeneration, respectively, and do not manifest with this specific sleep profile. Anti-Ma2 is associated with diencephalic encephalitis and hypersomnia (narcolepsy-like) but lacks the characteristic stridor and complex parasomnias. Anti-NMDA receptor encephalitis presents with psychiatric symptoms, seizures, and dyskinesias. The item is medically accurate, logically sound, and tests a specific, well-defined syndrome.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nThe vignette describes the classic clinical phenotype of anti-IgLON5 disease, a distinct autoimmune tauopathy. The key discriminating features are the specific sleep architecture (coexistence of REM sleep behavior disorder and non-REM parasomnias), nocturnal stridor (due to laryngeal dysfunction), gait instability, and cognitive decline. These findings point uniquely to Option C. The distractors are incorrect: Anti-Hu and Anti-Yo are typically associated with paraneoplastic sensory neuronopathy or cerebellar degeneration, respectively, and do not manifest with this specific sleep profile. Anti-Ma2 is associated with diencephalic encephalitis and hypersomnia (narcolepsy-like) but lacks the characteristic stridor and complex parasomnias. Anti-NMDA receptor encephalitis presents with psychiatric symptoms, seizures, and dyskinesias. The item is medically accurate, logically sound, and tests a specific, well-defined syndrome.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette presents a classic case of Placental Site Trophoblastic Tumor (PSTT). Key discriminating clues include the clinical history (18 months post-term delivery), the specific lab profile (mildly elevated hCG, unlike the very high levels in choriocarcinoma), and the pathognomonic histology (intermediate trophoblasts, low mitotic index). Crucially, the immunohistochemical profile—strongly positive for human placental lactogen (hPL) and negative/weak for hCG—uniquely identifies PSTT. Choriocarcinoma (A) and invasive mole (E) are ruled out by the low hCG and lack of biphasic/villous histology. Epithelioid Trophoblastic Tumor (C) is the primary distractor as it also arises from intermediate trophoblasts; however, PSTT is characterized by diffuse/strong hPL positivity, whereas ETT typically shows focal hPL and diffuse p63 positivity. The description 'sheets... strongly positive for hPL' makes PSTT the definitive best answer. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette presents a classic case of Placental Site Trophoblastic Tumor (PSTT). Key discriminating clues include the clinical history (18 months post-term delivery), the specific lab profile (mildly elevated hCG, unlike the very high levels in choriocarcinoma), and the pathognomonic histology (intermediate trophoblasts, low mitotic index). Crucially, the immunohistochemical profile—strongly positive for human placental lactogen (hPL) and negative/weak for hCG—uniquely identifies PSTT. Choriocarcinoma (A) and invasive mole (E) are ruled out by the low hCG and lack of biphasic/villous histology. Epithelioid Trophoblastic Tumor (C) is the primary distractor as it also arises from intermediate trophoblasts; however, PSTT is characterized by diffuse/strong hPL positivity, whereas ETT typically shows focal hPL and diffuse p63 positivity. The description 'sheets... strongly positive for hPL' makes PSTT the definitive best answer. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item correctly identifies a high-risk patient with Danon disease (LAMP2 mutation), characterized by massive hypertrophic cardiomyopathy (28 mm), multiple accessory pathways, and refractory pre-excited atrial fibrillation. Options A and C are medically contraindicated: Flecainide is unsafe in severe structural heart disease, and beta-blockers are contraindicated in pre-excited AF due to the risk of precipitating ventricular fibrillation. Option E (pacemaker) does not address the underlying pathology or arrhythmia. The key discrimination is between B (Ablation) and D (Transplant). While ablation is standard for typical WPW, Danon disease is a specific exception where pathways are often multiple, broad, and difficult to ablate with high recurrence rates. Moreover, the rapid progression of the cardiomyopathy to end-stage heart failure is the primary determinant of prognosis. Therefore, early evaluation for heart transplantation is the specific, board-tested management priority for this genetic condition, making D the unique best answer. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item correctly identifies a high-risk patient with Danon disease (LAMP2 mutation), characterized by massive hypertrophic cardiomyopathy (28 mm), multiple accessory pathways, and refractory pre-excited atrial fibrillation. Options A and C are medically contraindicated: Flecainide is unsafe in severe structural heart disease, and beta-blockers are contraindicated in pre-excited AF due to the risk of precipitating ventricular fibrillation. Option E (pacemaker) does not address the underlying pathology or arrhythmia. The key discrimination is between B (Ablation) and D (Transplant). While ablation is standard for typical WPW, Danon disease is a specific exception where pathways are often multiple, broad, and difficult to ablate with high recurrence rates. Moreover, the rapid progression of the cardiomyopathy to end-stage heart failure is the primary determinant of prognosis. Therefore, early evaluation for heart transplantation is the specific, board-tested management priority for this genetic condition, making D the unique best answer. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The patient presents with classic natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML), evidenced by the high JCV index, treatment duration >24 months, characteristic MRI findings, and positive CSF JCV PCR. The pathophysiology involves natalizumab blocking lymphocyte entry into the CNS, allowing viral replication. The cornerstone of treatment is immune reconstitution. Plasma exchange (PLEX) is the standard intervention cited in board examinations to rapidly accelerate the clearance of natalizumab (desaturating alpha-4 integrin receptors) and restore immune surveillance. While PLEX carries a risk of precipitating severe Immune Reconstitution Inflammatory Syndrome (IRIS), it is the only option listed that addresses the underlying mechanism to prevent fatal viral progression. Options A and B are contraindicated as they maintain immunosuppression. Options D (mirtazapine) and E (mefloquine) are historical considerations that lack clinical evidence of benefit. Therefore, C is the unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The patient presents with classic natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML), evidenced by the high JCV index, treatment duration >24 months, characteristic MRI findings, and positive CSF JCV PCR. The pathophysiology involves natalizumab blocking lymphocyte entry into the CNS, allowing viral replication. The cornerstone of treatment is immune reconstitution. Plasma exchange (PLEX) is the standard intervention cited in board examinations to rapidly accelerate the clearance of natalizumab (desaturating alpha-4 integrin receptors) and restore immune surveillance. While PLEX carries a risk of precipitating severe Immune Reconstitution Inflammatory Syndrome (IRIS), it is the only option listed that addresses the underlying mechanism to prevent fatal viral progression. Options A and B are contraindicated as they maintain immunosuppression. Options D (mirtazapine) and E (mefloquine) are historical considerations that lack clinical evidence of benefit. Therefore, C is the unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette presents a classic case of Schnitzler syndrome, characterized by the tetrad of chronic urticarial rash, recurrent fever, bone pain, and a monoclonal IgM gammopathy. The elevated ESR and CRP reflect the intense systemic inflammation associated with this condition. Schnitzler syndrome is an acquired autoinflammatory disorder driven by the activation of the NLRP3 inflammasome and the subsequent overproduction of Interleukin-1 beta (IL-1β). Therefore, IL-1 blockade (e.g., with anakinra or canakinumab) is the highly effective, first-line standard of care. While IL-6 is often elevated and drives the acute phase response (CRP), it is a downstream mediator; IL-1 is the primary pathogenic driver and therapeutic target. TNF-alpha inhibitors are generally ineffective. The question is medically accurate, the diagnosis is distinct, and the keyed answer is the unambiguous best choice based on current medical consensus.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette presents a classic case of Schnitzler syndrome, characterized by the tetrad of chronic urticarial rash, recurrent fever, bone pain, and a monoclonal IgM gammopathy. The elevated ESR and CRP reflect the intense systemic inflammation associated with this condition. Schnitzler syndrome is an acquired autoinflammatory disorder driven by the activation of the NLRP3 inflammasome and the subsequent overproduction of Interleukin-1 beta (IL-1β). Therefore, IL-1 blockade (e.g., with anakinra or canakinumab) is the highly effective, first-line standard of care. While IL-6 is often elevated and drives the acute phase response (CRP), it is a downstream mediator; IL-1 is the primary pathogenic driver and therapeutic target. TNF-alpha inhibitors are generally ineffective. The question is medically accurate, the diagnosis is distinct, and the keyed answer is the unambiguous best choice based on current medical consensus.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette presents a classic case of Cerebrotendinous Xanthomatosis (CTX), characterized by the triad of juvenile cataracts, tendon xanthomas, and progressive neurologic dysfunction (ataxia), confirmed by elevated serum cholestanol. CTX is caused by a deficiency in CYP27A1, leading to impaired bile acid synthesis and a lack of chenodeoxycholic acid (CDCA). This deficiency causes a loss of negative feedback on cholesterol 7α-hydroxylase (CYP7A1), resulting in the overproduction of cholestanol. The standard of care and the specific treatment shown to halt neurologic progression is CDCA supplementation (Option B). CDCA restores the feedback loop, suppressing cholestanol production. While statins (Option A) are sometimes used as adjunctive therapy, they are not the primary disease-modifying treatment and are insufficient on their own to normalize cholestanol metabolism or halt progression as effectively as CDCA. The other options are not indicated for CTX. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette presents a classic case of Cerebrotendinous Xanthomatosis (CTX), characterized by the triad of juvenile cataracts, tendon xanthomas, and progressive neurologic dysfunction (ataxia), confirmed by elevated serum cholestanol. CTX is caused by a deficiency in CYP27A1, leading to impaired bile acid synthesis and a lack of chenodeoxycholic acid (CDCA). This deficiency causes a loss of negative feedback on cholesterol 7α-hydroxylase (CYP7A1), resulting in the overproduction of cholestanol. The standard of care and the specific treatment shown to halt neurologic progression is CDCA supplementation (Option B). CDCA restores the feedback loop, suppressing cholestanol production. While statins (Option A) are sometimes used as adjunctive therapy, they are not the primary disease-modifying treatment and are insufficient on their own to normalize cholestanol metabolism or halt progression as effectively as CDCA. The other options are not indicated for CTX. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a classic presentation of OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Agenesis), also known as Herlyn-Werner-Wunderlich syndrome. The specific triad of findings—didelphic uterus, unilateral hematocolpos (indicating obstruction of one hemivagina), and ipsilateral renal agenesis—uniquely identifies this condition. The patient reports normal menses because the non-obstructed side is patent, while the obstructed side causes cyclic pain and hematocolpos. Option A (MRKH) is incorrect because it involves uterine aplasia. Option C (CAIS) involves a 46,XY karyotype and absence of a functional uterus. Option E (Imperforate hymen) typically causes primary amenorrhea and midline hematocolpos rather than the lateralized findings described. Option D (Transverse vaginal septum) describes an anatomical defect that can cause obstruction, but OHVIRA is the specific syndromic diagnosis that accounts for the renal agenesis and uterine anomaly together. The item is logically valid, medically accurate, and the key is correct.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a classic presentation of OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Agenesis), also known as Herlyn-Werner-Wunderlich syndrome. The specific triad of findings—didelphic uterus, unilateral hematocolpos (indicating obstruction of one hemivagina), and ipsilateral renal agenesis—uniquely identifies this condition. The patient reports normal menses because the non-obstructed side is patent, while the obstructed side causes cyclic pain and hematocolpos. Option A (MRKH) is incorrect because it involves uterine aplasia. Option C (CAIS) involves a 46,XY karyotype and absence of a functional uterus. Option E (Imperforate hymen) typically causes primary amenorrhea and midline hematocolpos rather than the lateralized findings described. Option D (Transverse vaginal septum) describes an anatomical defect that can cause obstruction, but OHVIRA is the specific syndromic diagnosis that accounts for the renal agenesis and uterine anomaly together. The item is logically valid, medically accurate, and the key is correct.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Miskeyed (K). The clinical vignette describes a patient with HeartMate 3 (HM3) pump thrombosis (hemolysis, power spikes, inflow obstruction). According to ISHLT guidelines and standard of care, the most appropriate *immediate* management for suspected pump thrombosis is the initiation of intravenous unfractionated heparin (Option B) to achieve therapeutic PTT, provided there are no contraindications. While thrombolysis is a treatment option for thrombosis refractory to heparin or in hemodynamically unstable patients, 'intrapump alteplase via percutaneous catheter' (Option D) is a highly specialized, invasive, and logisticaly complex intervention that would not replace the immediate initiation of heparin in the acute setting. Furthermore, intrapump thrombolysis is not the universal standard of care over systemic thrombolysis or surgical exchange, and certainly not the first step 'upon presentation' before anticoagulation. By forcing a choice between the standard initial step (B) and a specialized downstream intervention (D), and keying the latter, the item is miskeyed regarding 'immediate management.'\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Miskeyed (K). The clinical vignette describes a patient with HeartMate 3 (HM3) pump thrombosis (hemolysis, power spikes, inflow obstruction). According to ISHLT guidelines and standard of care, the most appropriate *immediate* management for suspected pump thrombosis is the initiation of intravenous unfractionated heparin (Option B) to achieve therapeutic PTT, provided there are no contraindications. While thrombolysis is a treatment option for thrombosis refractory to heparin or in hemodynamically unstable patients, 'intrapump alteplase via percutaneous catheter' (Option D) is a highly specialized, invasive, and logisticaly complex intervention that would not replace the immediate initiation of heparin in the acute setting. Furthermore, intrapump thrombolysis is not the universal standard of care over systemic thrombolysis or surgical exchange, and certainly not the first step 'upon presentation' before anticoagulation. By forcing a choice between the standard initial step (B) and a specialized downstream intervention (D), and keying the latter, the item is miskeyed regarding 'immediate management.'", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). The vignette presents a classic board-exam setup for Granulomatous Amebic Encephalitis (GAE), likely caused by Balamuthia mandrillaris. Key discriminating features include the subacute course (3 weeks), immunocompetent status, specific risk factor (gardener/soil exposure), ring-enhancing lesions, lymphocytic pleocytosis, and negative standard bacterial/fungal workup. These clues collectively exclude bacterial brain abscess (usually acute/neutrophilic), fungal infection (negative cultures), and Primary Amebic Meningoencephalitis (acute/fulminant, caused by Naegleria). The keyed answer (B) correctly identifies the core components of the recommended multidrug regimen for Balamuthia (miltefosine and albendazole). While real-world treatment often involves additional agents (e.g., fluconazole, azithromycin), Option B is the only choice targeting the specific etiology implied by the stem. The other options treat pathologies (PAM, bacterial abscess, CMV, fungal) that are effectively ruled out by the vignette's details. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). The vignette presents a classic board-exam setup for Granulomatous Amebic Encephalitis (GAE), likely caused by Balamuthia mandrillaris. Key discriminating features include the subacute course (3 weeks), immunocompetent status, specific risk factor (gardener/soil exposure), ring-enhancing lesions, lymphocytic pleocytosis, and negative standard bacterial/fungal workup. These clues collectively exclude bacterial brain abscess (usually acute/neutrophilic), fungal infection (negative cultures), and Primary Amebic Meningoencephalitis (acute/fulminant, caused by Naegleria). The keyed answer (B) correctly identifies the core components of the recommended multidrug regimen for Balamuthia (miltefosine and albendazole). While real-world treatment often involves additional agents (e.g., fluconazole, azithromycin), Option B is the only choice targeting the specific etiology implied by the stem. The other options treat pathologies (PAM, bacterial abscess, CMV, fungal) that are effectively ruled out by the vignette's details. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), characterized by early-onset strokes, livedo racemosa, vasculopathy, and specific immunologic findings (low IgM). The diagnosis is confirmed by genetics. Current medical consensus and guidelines establish anti-TNF agents (specifically Etanercept or Adalimumab) as the first-line and most effective treatment for the vasculitic phenotype of DADA2 to prevent recurrent strokes. While corticosteroids and cyclophosphamide are standard for other vasculitides, DADA2 is notably resistant to these or requires toxic doses, whereas anti-TNF therapy is highly effective. Hematopoietic stem cell transplantation is reserved for severe hematologic/immunodeficient phenotypes (bone marrow failure), which are not the primary focus of this vignette (strokes/vasculitis dominate). Therefore, Etanercept is the unambiguous best answer among the choices provided. The item is medically accurate, logically sound, and aligns with current literature.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), characterized by early-onset strokes, livedo racemosa, vasculopathy, and specific immunologic findings (low IgM). The diagnosis is confirmed by genetics. Current medical consensus and guidelines establish anti-TNF agents (specifically Etanercept or Adalimumab) as the first-line and most effective treatment for the vasculitic phenotype of DADA2 to prevent recurrent strokes. While corticosteroids and cyclophosphamide are standard for other vasculitides, DADA2 is notably resistant to these or requires toxic doses, whereas anti-TNF therapy is highly effective. Hematopoietic stem cell transplantation is reserved for severe hematologic/immunodeficient phenotypes (bone marrow failure), which are not the primary focus of this vignette (strokes/vasculitis dominate). Therefore, Etanercept is the unambiguous best answer among the choices provided. The item is medically accurate, logically sound, and aligns with current literature.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]